(UL) Unilever - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US9047677045
Stock:
Total Rating 58
Risk 80
Buy Signal -0.57
| Risk 5d forecast | |
|---|---|
| Volatility | 23.5% |
| Relative Tail Risk | -7.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | 8.24 |
| Character TTM | |
|---|---|
| Beta | -0.029 |
| Beta Downside | -0.292 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.93% |
| CAGR/Max DD | 0.73 |
Description: UL Unilever
Unilever PLC operates as a fast-moving consumer goods company in the Asia Pacific, Africa, the Americas, and Europe. It operates through Beauty & Wellbeing, Personal Care, Home Care, and Foods segments. The Beauty & Wellbeing segment engages in the sale of hair care products, such as shampoo, conditioner, and styling; skin care products, including face, hand, and body moisturizers; and Prestige beauty and wellbeing products. The Personal Care segment offers skin cleansing products comprising soaps and showers; deodorants; and oral care products consisting of toothpaste, toothbrush, and mouthwash products. The Home Care segment is involved in the sale of fabric care products, including washing powders and liquids, and rinse conditioners; and fabric enhancers, and home and hygiene cleaning products. The Foods segment provides cooking aids and mini meals, such as soups, bouillons, and seasonings, as well as condiments, mayonnaise and ketchup, and food solutions. The company provides its products under the AXE, Ben & Jerry's, Clear, Cif, Closeup, Comfort, Cornetto, Dermalogica, Domestos, Dove, Dove Men+Care, Hellmann's, Horlicks, Knorr, LUX, Lifebuoy, Liquid I.V., Nutrafol, OMO, Pond's, Paula's Choice, Pepsodent, Rexona, Sunlight, Sunsilk, Surf, TRESemmé, Vaseline, Wall's, and Yasso brand names. Unilever PLC was founded in 1860 and is headquartered in London, the United Kingdom.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 11.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 5.18 > 1.0 |
| NWC/Revenue: -4.13% < 20% (prev -6.27%; Δ 2.14% < -1%) |
| CFO/TA 0.26 > 3% & CFO 18.04b > Net Income 11.82b |
| Net Debt (25.65b) to EBITDA (24.12b): 1.06 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.20b) vs 12m ago -13.16% < -2% |
| Gross Margin: 69.99% > 18% (prev 0.25%; Δ 6974 % > 0.5%) |
| Asset Turnover: 152.8% > 50% (prev 118.9%; Δ 33.91% > 0%) |
| Interest Coverage Ratio: 14.01 > 6 (EBITDA TTM 24.12b / Interest Expense TTM 1.50b) |
Altman Z'' 2.98
| A: -0.07 (Total Current Assets 17.06b - Total Current Liabilities 21.65b) / Total Assets 70.44b |
| B: 0.63 (Retained Earnings 44.21b / Total Assets 70.44b) |
| C: 0.29 (EBIT TTM 21.06b / Avg Total Assets 72.83b) |
| D: -0.55 (Book Value of Equity -29.04b / Total Liabilities 52.86b) |
| Altman-Z'' Score: 2.98 = A |
Beneish M -3.32
| DSRI: 1.25 (Receivables 7.67b/4.94b, Revenue 111.26b/89.41b) |
| GMI: 0.35 (GM 69.99% / 24.55%) |
| AQI: 1.02 (AQ_t 0.63 / AQ_t-1 0.62) |
| SGI: 1.24 (Revenue 111.26b / 89.41b) |
| TATA: -0.09 (NI 11.82b - CFO 18.04b) / TA 70.44b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of UL shares?
As of March 04, 2026, the stock is trading at USD 69.15 with a total of 4,826,308 shares traded.
Over the past week, the price has changed by -6.59%, over one month by +0.76%, over three months by +4.23% and over the past year by +9.84%.
Over the past week, the price has changed by -6.59%, over one month by +0.76%, over three months by +4.23% and over the past year by +9.84%.
Is UL a buy, sell or hold?
Unilever has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy UL.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.8 | 9.6% |
| Analysts Target Price | 75.8 | 9.6% |
UL Fundamental Data Overview March 04, 2026
P/E Trailing = 23.4361
P/E Forward = 19.6078
P/S = 3.0948
P/B = 8.7819
P/EG = 2.2271
Revenue TTM = 111.26b USD
EBIT TTM = 21.06b USD
EBITDA TTM = 24.12b USD
Long Term Debt = 25.70b USD (from longTermDebt, last quarter)
Short Term Debt = 2.58b USD (from shortTermDebt, last quarter)
Debt = 29.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.65b USD (from netDebt column, last quarter)
Enterprise Value = 181.95b USD (156.30b + Debt 29.59b - CCE 3.94b)
Interest Coverage Ratio = 14.01 (Ebit TTM 21.06b / Interest Expense TTM 1.50b)
EV/FCF = 12.26x (Enterprise Value 181.95b / FCF TTM 14.84b)
FCF Yield = 8.16% (FCF TTM 14.84b / Enterprise Value 181.95b)
FCF Margin = 13.34% (FCF TTM 14.84b / Revenue TTM 111.26b)
Net Margin = 10.62% (Net Income TTM 11.82b / Revenue TTM 111.26b)
Gross Margin = 69.99% ((Revenue TTM 111.26b - Cost of Revenue TTM 33.39b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.58 (Enterprise Value 181.95b / Total Assets 70.44b)
Interest Expense / Debt = 1.57% (Interest Expense 464.5m / Debt 29.59b)
Taxrate = 33.81% (1.10b / 3.26b)
NOPAT = 13.94b (EBIT 21.06b * (1 - 33.81%))
Current Ratio = 0.79 (Total Current Assets 17.06b / Total Current Liabilities 21.65b)
Debt / Equity = 1.91 (Debt 29.59b / totalStockholderEquity, last quarter 15.52b)
Debt / EBITDA = 1.06 (Net Debt 25.65b / EBITDA 24.12b)
Debt / FCF = 1.73 (Net Debt 25.65b / FCF TTM 14.84b)
Total Stockholder Equity = 18.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.23% (Net Income 11.82b / Total Assets 70.44b)
RoE = 64.23% (Net Income TTM 11.82b / Total Stockholder Equity 18.40b)
RoCE = 47.76% (EBIT 21.06b / Capital Employed (Equity 18.40b + L.T.Debt 25.70b))
RoIC = 47.93% (NOPAT 13.94b / Invested Capital 29.09b)
WACC = 5.05% (E(156.30b)/V(185.89b) * Re(5.81%) + D(29.59b)/V(185.89b) * Rd(1.57%) * (1-Tc(0.34)))
Discount Rate = 5.81% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -6.81%
[DCF] Terminal Value 88.43% ; FCFF base≈13.69b ; Y1≈16.89b ; Y5≈28.76b
[DCF] Fair Price = 371.5 (EV 837.42b - Net Debt 25.65b = Equity 811.77b / Shares 2.18b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -11.90 | EPS CAGR: -61.30% | SUE: 0.0 | # QB: 0
Revenue Correlation: 6.50 | Revenue CAGR: -7.55% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.19 | Chg7d=+0.110 | Chg30d=+0.105 | Revisions Net=+0 | Growth EPS=+3.4% | Growth Revenue=+1.7%
EPS next Year (2027-12-31): EPS=3.41 | Chg7d=-0.004 | Chg30d=-0.114 | Revisions Net=-1 | Growth EPS=+7.0% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +0.0% (Analyst 3.7% - Implied 3.7%)
P/E Forward = 19.6078
P/S = 3.0948
P/B = 8.7819
P/EG = 2.2271
Revenue TTM = 111.26b USD
EBIT TTM = 21.06b USD
EBITDA TTM = 24.12b USD
Long Term Debt = 25.70b USD (from longTermDebt, last quarter)
Short Term Debt = 2.58b USD (from shortTermDebt, last quarter)
Debt = 29.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.65b USD (from netDebt column, last quarter)
Enterprise Value = 181.95b USD (156.30b + Debt 29.59b - CCE 3.94b)
Interest Coverage Ratio = 14.01 (Ebit TTM 21.06b / Interest Expense TTM 1.50b)
EV/FCF = 12.26x (Enterprise Value 181.95b / FCF TTM 14.84b)
FCF Yield = 8.16% (FCF TTM 14.84b / Enterprise Value 181.95b)
FCF Margin = 13.34% (FCF TTM 14.84b / Revenue TTM 111.26b)
Net Margin = 10.62% (Net Income TTM 11.82b / Revenue TTM 111.26b)
Gross Margin = 69.99% ((Revenue TTM 111.26b - Cost of Revenue TTM 33.39b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.58 (Enterprise Value 181.95b / Total Assets 70.44b)
Interest Expense / Debt = 1.57% (Interest Expense 464.5m / Debt 29.59b)
Taxrate = 33.81% (1.10b / 3.26b)
NOPAT = 13.94b (EBIT 21.06b * (1 - 33.81%))
Current Ratio = 0.79 (Total Current Assets 17.06b / Total Current Liabilities 21.65b)
Debt / Equity = 1.91 (Debt 29.59b / totalStockholderEquity, last quarter 15.52b)
Debt / EBITDA = 1.06 (Net Debt 25.65b / EBITDA 24.12b)
Debt / FCF = 1.73 (Net Debt 25.65b / FCF TTM 14.84b)
Total Stockholder Equity = 18.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.23% (Net Income 11.82b / Total Assets 70.44b)
RoE = 64.23% (Net Income TTM 11.82b / Total Stockholder Equity 18.40b)
RoCE = 47.76% (EBIT 21.06b / Capital Employed (Equity 18.40b + L.T.Debt 25.70b))
RoIC = 47.93% (NOPAT 13.94b / Invested Capital 29.09b)
WACC = 5.05% (E(156.30b)/V(185.89b) * Re(5.81%) + D(29.59b)/V(185.89b) * Rd(1.57%) * (1-Tc(0.34)))
Discount Rate = 5.81% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -6.81%
[DCF] Terminal Value 88.43% ; FCFF base≈13.69b ; Y1≈16.89b ; Y5≈28.76b
[DCF] Fair Price = 371.5 (EV 837.42b - Net Debt 25.65b = Equity 811.77b / Shares 2.18b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -11.90 | EPS CAGR: -61.30% | SUE: 0.0 | # QB: 0
Revenue Correlation: 6.50 | Revenue CAGR: -7.55% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.19 | Chg7d=+0.110 | Chg30d=+0.105 | Revisions Net=+0 | Growth EPS=+3.4% | Growth Revenue=+1.7%
EPS next Year (2027-12-31): EPS=3.41 | Chg7d=-0.004 | Chg30d=-0.114 | Revisions Net=-1 | Growth EPS=+7.0% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +0.0% (Analyst 3.7% - Implied 3.7%)